Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001:1:12.
doi: 10.1186/1471-2407-1-12. Epub 2001 Aug 21.

Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas

L Mastronardi  1 , A Guiducci, F Puzzilli
Affiliations

Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas

L Mastronardi et al. BMC Cancer. 2001.

Abstract

Aims and background: The Ki-67 is a nuclear antigen detected by the monoclonal antibody MIB-1 and its Labeling Index (LI) is considered a marker of normal and abnormal cell proliferation. Pituitary adenomas are generally well differentiated neoplasms, even if in about one third of cases they are invasive of surrounding tissues. The aim of this study is to evaluate the correlation between Ki-67 labelling index and tumor size of pituitary adenomas extimated by means CT and MRI and confirmed at operation.

Methods: Using the monoclonal antibody MIB-1, we evaluated the expression of Ki-67 in 121 anterior pituitary adenomas consecutively operated on in a 48-month period.

Results: In relation to neuroradiological (CT and MRI) and surgically verified tumor size, we identified 24 microadenomas, 27 intrasellar macroadenomas, 34 intra-suprasellar macroadenomas, and 36 intra-supra-parasellar macroadenomas. The adenomas were non-infiltrating (76 cases) and infiltrating (45 cases) adenomas. The wall of the cavernous sinus (CS) was infiltrated in 18 cases. Forty-eight adenomas were non-functioning and 73 functioning. The overall mean +/- SD Ki-67 LI was 2.72 +/- 2.49% (median 1.6). It was 2.59 +/- 1.81 in microadenomas, 2.63 +/- 3.45 in intrasellar macroadenomas, 1.91 +/- 2.11 in intra-suprasellar macroadenomas, and 3.29 +/- 5.45 in intra-supra-parasellar macroadenomas (p = 0.27). It was 3.73 +/- 5.13% in infiltrating and 2.03 +/- 2.41% in non-infiltrating adenomas (p = 0.02), and 5.61 +/- 7.19% in CS-infiltrating versus 2.09 +/- 2.37% in CS-non-infiltrating adenomas (p = 0.0005).

Conclusions: Our preliminary results seem to exclude significative correlations between Ki-67 LI and tumor size of anterior pituitary adenomas, even if this index can be considered a useful marker in the determination of the infiltrative behaviour of these tumors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
MIB-1 immunostaining of a mixed (GH-PRL) infiltrating pituitary adenoma (original maginification, ×400). A high proportion of labeled nuclei are seen (Ki-67 LI = 10%).
See this image and copyright information in PMC

References

    1. Asano K, Kubo O, Tajika Y, Huang MC, Takakura K. The relationship between cell proliferation and secretory activity in pituitary adenomas. A review of 63 cases. No To Shinkei. 1996;48:543–549. - PubMed
    1. Atkin SL, Green VL, Hipkin LJ, Landolt AM, Foy PM, Jeffreys RV, et al. A comparison of proliferation indices in human anterior pituitary adenomas using formalin-fixed tissue and in vitro cell culture. J Neurosurg. 1997;87:85–88. - PubMed
    1. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology. 1990;17:489–503. - PubMed
    1. Buchfelder M, Fahlbusch R, Adams EF, Kiesewetter F, Thierauf P. Proliferation parameters for pituitary adenomas. Acta Neurochir Suppl (Wien) 1996;65:18–21. - PubMed
    1. Daita G, Yonemasu Y. Dural invasion and proliferative potential of pituitary adenomas. Neurol Med Chir. 1996;36:211–214. - PubMed

LinkOut - more resources